BIOTECH THAWS OUT:
“Small drug discovery firms are capitalizing on the positive momentum that’s returned to the market for biotechnology stocks. A dozen have announced plans this quarter to launch initial public stock offerings (IPOs), while nearly as many more hope to raise money through follow-on bids. The upturn, if it persists, may help rescue a sector where limited cash flow has precipitated major cutbacks and consolidation.”